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Abstract
Germ cell tumours predominantly of the testis ((T)GCTs) are remarkably chemother-
apy sensitive. However, a small proportion of patients fail to be cured with cis-
platin‐based combination chemotherapy. miR‐371a‐3p is a new liquid biopsy
biomarker for (T)GCTs. The aim of this study was to evaluate clinical utility of
plasma miR‐371a‐3p level in patients starting systemic chemotherapy. Patients were
included before the first cycle (N = 180) and second cycle (N = 101) of systemic
first line chemotherapy, treated between July 2010 and May 2017. Plasma miR‐
371a‐3p levels were measured with the ampTSmiR test and compared to disease
characteristics and outcome. Pretreatment plasma miR‐371a‐3p levels were
increased in 51.7% of cases and associated with number of metastatic sites, pres-
ence of lung, retroperitoneal, and mediastinal lymph node metastases, S – stage,
IGCCCG risk group, and response to therapy. Patients with a negative pretreatment
plasma level had better progression‐free survival (PFS) and overall survival (OS)
compared to patients being positive for miR‐371a‐3p (hazard ratio [HR] = 0.26, 95%
confidence interval [CI] 0.09‐0.71, P = 0.02 for PFS and HR = 0.21, 95% CI 0.07‐
0.67, P = 0.03 for OS, respectively). Patients negative for miR‐371a‐3p in both sam-
ples had a superior PFS (HR = 0.10, 95% CI 0.01‐21.49, P = 0.02) and OS (HR =
0.08, 95% CI 0.01‐27.81, P = 0.008) compared to patients with miR‐371a‐3p posi-
tive in both samples (multivariate analyses were non‐significant). In total 68% of the
patients were S0. This study demonstrates clinical value of plasma miR‐371a‐3p
level in chemotherapy naïve (T)GCT patients starting first line of chemotherapy to
predict prognosis.
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1 | INTRODUCTION
Testicular germ cell tumours (TGCTs) are rare, although they are the
most common cancer in young Caucasian males, accounting for 60% of
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all malignancies in the age group between 20 and 40 years.1,2 TGCTs
represent a highly curable malignancy. In fact, cisplatin based chemother-
apy is the mainstay in the treatment of TGCTs, resulting in about 70%‐
80% cure of patients with disseminated disease with a multimodality
approach. However, between 20% and 30% of patients do not respond
or relapse with this treatment protocol.2,3 About 20%‐25% of patients
with relapsed TGCTs may be cured with various approaches, including
salvage chemotherapy based on high‐dose chemotherapy with autolo-
gous hematopoietic stem‐cell rescue or combined with standard cisplatin
dose and previously non‐utilized drugs.4-6
Currently, the clinical management of advanced TGCT disease is
based on classical serum protein markers (alpha‐fetoprotein [AFP], β‐
human chorionic gonadotropin [HCG], and lactate dehydrogenase
[LDH]), and imaging studies.7,8 However, only 60% of TGCTs demon-
strate elevated serum tumour markers at initial diagnosis. Therefore, in
advanced cases, there is a need to identify reliable markers capable of
determining chemotherapy effectiveness and patients’ outcome.
microRNAs (miRNAs) are involved in important biological processes,
both normal as well as pathological, including various types of cancer.
As the discovery of specific embryonic stem cell related miRNAs as
relevant oncogenes in TGCTs,9 various studies evaluated their role in
tissues and body fluids of (T)GCT patients.9-17
In the largest series to date of 250 TGCT patients, 60 non‐TGCT
patients at primary diagnosis and 104 male healthy donors, the detection
of miR‐371a‐3p, 373‐3p, and 367‐3p in sera with the ampTSmiR test
was highly informative to diagnose patients with the primary TGCTs.
The data showed an area under the curve (AUC) of 0.96, with a 90%
sensitivity and 91% specificity.14 In an independent study performed
with a slightly different protocol and consisting of a series of sera from
166 TGCTs patients and 118 male controls, a positive miR‐371a‐3p level
was found in 88.7% of the patients with the AUC of 0.94, and a 93.4%
specificity.10 Both studies demonstrated that the detection of miR‐371a‐
3p in serum is far more sensitive and specific than the classical serum
markers β‐HCG, AFP, and LDH. Furthermore, the miR‐371a‐3p levels
correlate with tumour burden and treatment results.10 In addition, the
four‐serum embryonic stem cell related miRNA panel (including miR‐
371a‐3p, miR‐372‐3p, miR‐373‐3p, and miR‐367‐3p) also showed a high
sensitivity/specificity for diagnosing pediatric (mainly extra‐gonadal)
GCTs, based on serum and cerebrospinal fluid analyses. It allowed early
detection of relapse of a single mixed tumour and distinguished intracra-
nial malignant GCTs from intracranial non‐GCTs at the time of diagno-
sis.15 In addition, the ampTSmiR test targeting miR‐371a‐3p used in our
laboratory is more sensitive than the conventional TGCTs protein serum
biomarkers for the detection of residual disease and relapse.13,14,18 In
conclusion, miR‐371a‐3p is the most promising miRNA for the detection
of (T)GCTs in body fluids to date, performed with a highly sensitive and
specific multiplexed pre‐amplification quantitative real‐time PCR (qRT‐
PCR) technique.10,14
However, in spite of the fact that miR‐371a‐3p is a promising
new specific biomarker for (T)GCTs, data related to its clinical utility
are still limited.9-12,18 The aim of this study was to evaluate clinical
utility of plasma miR‐371a‐3p level in chemo‐naïve GCTs patients
starting systemic chemotherapy.
2 | MATERIALS AND METHODS
2.1 | Study patients
This retrospective translational study (Protocol IZLO1, Chair: M.
Mego) was approved by the Institutional Review Board (IRB) of the
National Cancer Institute and was conducted between July 2010
and May 2017. All consecutive patients with TGCTs treated with
orchiectomy (except two patients that started treatment without
orchiectomy due to very advanced disease) and at least one cycle of
cisplatin‐based chemotherapy in the National Cancer Institute of Slo-
vakia and St. Elisabeth Cancer Institute in Slovakia were enrolled in
this prospective study. Data regarding age, tumour histological sub-
type, clinical stage, type, and number of sites of metastasis and type
of chemotherapy regimen were recorded in all the patients and com-
pared with plasma miR‐371a‐3p level (Table 1). TGCT patients were
recruited and consented according to the Institutional Review Board
approved protocol. The study adhered to the “Code for Proper Sec-
ondary Use of Human Tissue in The Netherlands” developed by the
Dutch Federation of Medical Scientific Societies (FMWV) (Version
2002, update 2011). STARD guidelines were followed to perform
this study.19
2.2 | Samples collection
Peripheral blood samples were collected from all translational study
participants into BD Vacutainer® EDTA tubes at baseline in the
morning on day −1 or 0 of the first cycle of chemotherapy (n = 180)
and before the second cycle of chemotherapy (n = 101). Patients’
blood samples (5 mL) were centrifuged at 2300 g for 10 minutes to
separate the plasma and blood cells. Collected plasma samples were
afterwards filtered through a 0.2 μm filter to remove larger particles.
Plasma aliquots were stored at −80°C until further analysis. In total,
281 plasma samples of 180 patients were analysed (Table 1). Median
age of patients was 30 years (range 16‐67 years).
The miRNA levels of (T)GCT patients were compared with
plasma levels of 50 male healthy donors, of which also serum was
available taken at the same time point. Plasma was collected using
Vacuette K3 EDTA Liquid, 6 ml vials (Greiner Bio‐One, Alphen aan
den Rijn, the Netherlands).
The median age was 54 (range 22‐70 years). In our previously
reported study, we showed that age did not influence the outcome
of the miRNA analysis in sera14 (additional samples Person coeffi-
cient of 0.2336, P = 0.26), nor did it influence the outcome in this
series of plasma samples. Because of the specific regulations it is not
allowed to have information related to clinical data of the control
group, except age, and gender. The donors of Sanquin are suppos-
edly healthy males, but not specifically checked for absence of a T
(GCT). However, based on the incidence in the Netherlands being
around 800 patients per year in a population of ~8 million males,
the chance of including a patient is very low. It was not possible to
collect large numbers of control plasmas in Slovenia. However, both
populations were from Caucasian origin. At present no reports were
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made according to population differences and expression of miR‐371
in T(GCT). The normal control plasma samples were obtained from
Sanquin (Amsterdam, the Netherlands).
2.3 | miRNA purification and RT‐qPCR
For the ampTSmiR tests specific miRNAs were isolated from
50 μL plasma using target‐specific anti‐miRNA magnetic beads as
described before.14 In short, cDNA generation and quantification
of miRNA levels were performed with a highly sensitive multi-
plexed pre‐amplification quantitative RT‐PCR technique (ampTSmiR
test). The following TaqMan MicroRNA assays were used: catalog
ID: hsa‐miR‐371a‐3p (002124); ath‐miR‐159a (000338), and hsa‐
miR‐30b‐5p (000602) (Thermo Fisher Scientific, Bleiswijk, the
Netherlands): In brief 5 μL of specifically targeted purified miRNA
in elution buffer was reverse transcribed into miRNA‐specific
cDNA with a TAQMAN(R) MICRORNA RT KIT (Thermo Fisher
Scientific), followed by a 13‐cycle pre‐amplification step using 2x
TaqMan Preamp Master mix (4488593, detailed protocol by sup-
plier Thermo Fisher Scientific) and 20x TaqMan MicroRNA Assays.
Thermal‐cycling conditions: 95°C for 10 minutes, followed by 13
cycles of 95°C for 15 seconds and 60°C for 1 minute. miRNA
levels were determined in 1.5 μL of cDNA on a TaqMan 7500
Real‐Time PCR system, according to the supplier (Thermo Fisher
Scientific).
2.4 | Quality control
A non‐human miRNA spike‐in ath‐miR‐159a was added in the same
fixed amount to the sera (0.2 μL of a 1 nmol/L stock solution) for
quality control of RNA isolation and cDNA generation. For calibra-
tion of input miRNA levels ath‐miR‐159a was used. All plasma sam-
ples were visually inspected and no hemolytic samples were
present that could lead to false interpretation of the results. No
samples had to be excluded due to poor miRNA recovery, based on
recovery of the spike‐in ath‐mir‐159a (variation in Ct generally
within ± 2 Cts, n = 301, SD < 1.67). For normalization the mean
levels of the endogenous reference miRNA (miR‐30b‐5p) were used
as described before.14,15 In each cDNA synthesis experiment, five
10‐fold dilution series of purified miRNA of the TCam‐2 seminoma
cell line was included for quality control and qPCR efficiency and
interplate calibration. For negative control, the no template control,
elution buffer was added instead of purified miRNA as described
previously.14
TABLE 1 Patients’ characteristics
Variable N %
All patients 180 100.0
Histology
Seminoma 51 28.3
Non‐seminoma 127 70.6
Unknown* 2 1.1
Primary tumour localization
Testicular 169 93.9
Extragonadal 11 6.1
IGCCCG risk group 105 58.3
Good risk 21 11.7
Intermediate risk 22 12.2
Poor risk 32 17.8
Sites of metastases 45 25.0
Retroperitoneum 109 60.6
Mediastinum 26 14.4
Lungs – –
Liver 57 31.7
Brain 123 68.3
Other – –
Visceral non‐pulmonary metastases 159 88.3
No. of metastatic site
0 21 11.7
1 144 80.0
2 36 20.0
>3 – –
Staging (UICC)
IA 5 2.8
IB 27 15.0
IS 13 7.2
IIA 19 10.6
IIB 26 14.4
IIC 16 8.9
IIIA 26 14.4
IIIB 21 11.7
IIIC 27 15.0
Response to therapy
Favourable response 173 96.1
Unfavourable response 7 3.9
Plasma samples
Samples before first cycle of chemotherapy 180 100.0
Samples before second cycle of chemotherapy 101 56.1
No. of positive samples
(Continues)
TABLE 1 (Continued)
Variable N %
Before first cycle of chemotherapy 93 51.7
Before second cycle of chemotherapy 4 2.2
Median value of miR‐371a‐3p
Before first cycle of chemotherapy (range) 1.2 0‐477.4
Before second cycle of chemotherapy (range) 0.0 0‐8.6
IGCCCG, International Germ Cell Consensus Classification Group; UICC,
Union for International Cancer Control.
*Diagnosis based on typical clinical presentation and highly elevated
serum tumour markers.
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2.5 | Evaluation
The target miRNA level per sample was determined according to
2−ΔΔCT method.15 Threshold for miR‐371a‐3p was calculated using
plasma samples of healthy donors analysed in this study (Figure S1).
A cut‐off value of ≥2.0 (Ct = 29.26) of the highest level (Ct = 30.26)
observed in the healthy donor group was used to dichotomize the
samples in two categories as positive or negative (cut‐off for miR‐
371a‐3p = 1) as described earlier.15 Plasma samples of healthy
donors (n = 50) contained similar minimal levels of miR‐371a‐3p as
matched sera, and control sera used in a previous study (n = 104)14
(Figure S1).
2.6 | Statistical analysis
Patient data were tabulated. The patients’ characteristics were sum-
marized using the mean or median (range) for continuous variables
and frequency (percentage) for categorical variables, respectively.
Statistical analysis was performed using non‐parametric tests as the
distribution of the miR‐371a‐3p levels was significantly different
from the normal distribution (Shapiro‐Wilk test). The Mann‐Whitney
U test was used for the analysis of the association of the miR‐371a‐
3p expression to clinicopathological variables between the two
groups of patients, and Kruskal‐Wallis test among more than two
groups, whereas Fisher's exact test or the χ2 test were used when
miR‐371a‐3p expression was categorized as positive or negative.
Wilcoxon test was used to compare plasma the miR‐371a‐3p before
the first and second cycle of chemotherapy. Pearson's correlations
were used to determine correlation between serum tumour markers
and plasma miR‐371a‐3p.
Median follow‐up period was calculated from the date of the
starting treatment with cisplatin‐based chemotherapy, as a median
observation time among all patients and among those still alive at
the time of their last follow‐up. Progression‐free survival (PFS) was
calculated from the date of the starting treatment with cisplatin‐
based chemotherapy to the date of progression or death or the
date of the last adequate follow‐up. Overall survival (OS) was cal-
culated from the date of starting treatment with cisplatin‐based
chemotherapy to the date of death or last follow‐up. Survival rates
were estimated using the Kaplan‐Meier product limits method and
were compared with the log‐rank test to determine significance.
miR‐371a‐3p expression data were dichotomized into positive and
negative based on the miR‐371a‐3p plasma level (see above). A
multivariate Cox proportional hazards model for PFS and OS was
used to assess differences in outcome on the basis of the miR‐
371a‐3p expression in primary tumour and/or biopsy of metastatic
site and prognosis according to the IGCCCG (International Germ
Cell Collaborative Group) criteria (IGCCCG, 1997). The Pearson cor-
relation coefficient was used to examine a correlation between
miR‐371a‐3p plasma levels and S‐stage (as defined by IGCCCG cri-
teria; S0 within normal limits; S1, AFP < 1000 ng/mL and/or β‐
HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2,
AFP 1000‐10 000 ng/mL and/or β‐HCG 5000‐50 000 mIU/mL and/
or LDH 1.5‐10 U/L upper normal limit; S3 AFP > 10 000 ng/mL
and/or β‐HCG > 50 000 mIU/mL and/or LDH > 10 U/L upper nor-
mal limit).
Data processing and statistical analysis were performed using
Microsoft Excel 2010, GraphPad Prism 7 (GraphPad Software, La
Jolla, CA, USA) and NCSS software (NCSS, LLC, East Kaysville, Utah,
USA). A P < 0.05 was considered statistically significant.
3 | RESULTS
3.1 | Patient characteristics
From July 2010 and May 2017, 180 patients starting adjuvant and/
or new line of chemotherapy were registered to the study. Basic
characteristic of the patients is shown in Table 1. The majority of
patients had primary TGCT (93.9%) and non‐seminoma histology
(70.6%). The study population included 32 patients with stage I dis-
ease (five patients stage IA and 27 patients stage IB) treated with
adjuvant chemotherapy. All these patients had non‐seminoma histol-
ogy, in 27 of tumours (84.4%) lymph vascular invasion was present,
while, 29 of them exhibit (90.6%) embryonal carcinoma component.
No relapse and/or death was observed in patients with stage I dis-
ease.
All patients were treated with platinum‐based chemotherapy, the
majority received BEP (bleomycin, etoposide, cisplatin) regimen 142
(78.9%), 23 patients (12.8%) received EP (etoposide, cisplatin)
chemotherapy, 6 (3.3%) received TIP (paclitaxel, ifosfamide, cisplatin)
chemotherapy, five patients (2.8%) VIP (etoposide, ifosfamide, cis-
platin), and four patients (2.2%) were treated with dose‐dense
chemotherapy.19
3.2 | Association between plasma miR‐371a‐3p
level and patients/tumour characteristics
Analysis between plasma miR‐371a‐3p level and patients/tumour
characteristics included all 180 patients. Pretreatment plasma miR‐
371a‐3p levels were significantly associated with IGCCCG risk
group, number of metastatic sites, presence of retroperitoneal and
mediastinal lymph node metastases, lung metastases, S – stage, and
favourable response to therapy (Table 2). These associations were
consistent for plasma miR‐371a‐3p as continuous variable or dichot-
omized as positive vs negative, except for response to therapy.
Subgroup analysis showed that both associations were triggered
mainly by non‐seminomas (Tables S1 and S1), where plasma miR‐
371a‐3p was associated with primary localization of the tumour as
well. In S0 stage patients that represented 73 (40.6%) of study pop-
ulation, there were no associations between plasma miR‐371a‐3p
and disease characteristics (Table S3). None of the five patients
with stage IA were miR‐371a‐3p positive, while four out of 27
patients (29.6%) with stage IB were miR‐371a‐3p positive and two
out of 13 (15.4%) of patients with IS stage were miR‐371a‐3p posi-
tive. Overall, six of 45 patients (13.3%) with CSI were miR‐371a‐3p
positive.
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TABLE 2 Association between miR‐371a‐3p and patients/tumour characteristics
Variable N Mean SEM Median P‐value
Negative Positive
P‐valueN % N %
All patients 180 25.5 1.2 4.9 NA 87 48.3 93 51.7 NA
Histology
Seminoma 51 36.6 3.4 9.2 0.23 19 37.3 32 62.7 0.07
Non‐seminoma 127 21.1 0.8 5.8 68 53.5 59 46.5
Unknown histology 2
Tumour primary
Primary TGCTs 169 25.2 1.1 5.0 0.46 82 48.5 87 51.5 1.00
Extragonadal GCTs 11 30.7 7.9 19.7 5 45.5 6 54.5
IGCCCG risk group
Good risk 105 18.7 1.6 6.1 <0.00001 48 45.7 57 54.3 <0.00001
Intermediate risk 21 57.0 22.7 13.6 6 28.6 15 71.4
Poor risk 22 63.2 14.7 13.3 5 22.7 17 77.3
Stage I (adjuvant therapy) 32 1.2 0.0 11.0 28 87.5 4 12.5
Number of metastatic sites
0 45 1.1 0.0 9.1 <0.00001 39 86.7 6 13.3 <0.00001
1‐2 109 22.3 3.3 5.8 42 38.5 67 61.5
>3 26 81.0 28.1 11.9 6 23.1 20 76.9
Retroperitoneal LN metastases
Absent 57 9.0 0.0 8.5 <0.00001 47 82.5 10 17.5 <0.00001
Present 123 33.1 5.5 5.8 40 32.5 83 67.5
Mediastinal lymph nodes metastases
Absent 159 16.2 0.9 4.8 0.00010 82 51.6 77 48.4 0.02
Present 21 95.9 28.5 13.1 5 23.8 16 76.2
Lung metastases
Absent 144 18.5 0.4 5.3 0.00001 79 54.9 65 45.1 0.001
Present 36 53.6 23.6 10.7 8 22.2 28 77.8
Liver metastases
Absent 169 23.2 1.0 5.0 0.18 84 49.7 85 50.3 0.21
Present 11 60.1 12.6 19.6 3 27.3 8 72.7
Non‐pulmonary visceral metastases
Absent 166 23.7 1.1 5.1 0.48 81 48.8 85 51.2 0.78
Present 14 47.3 5.6 17.4 6 42.9 8 57.1
S – stage*
0 73 2.3 0.0 7.0 <0.00001 53 72.6 20 27.4 <0.00001
1 61 20.0 2.1 7.6 25 41.0 36 59.0
2 27 61.2 22.7 11.5 6 22.2 21 77.8
3 19 81.4 25.9 13.7 3 15.8 16 84.2
Response to therapy
Favourable response 173 23.7 1.0 4.9 0.02 86 49.7 87 50.3 0.12
Unfavourable response 7 69.9 12.6 24.5 1 14.3 6 85.7
Statistically significant indicated bold.
TGCTs, testicular germ cell tumours; IGCCCG, International Germ Cell Consensus Classification Group*defined by IGCCCG criteria; S0, within normal
limits; S1, AFP < 1000 ng/mL and/or β‐HCG < 5000 mIU/mL and/or LDH < 1.5 U/L upper normal limit; S2, AFP 1000‐10 000 ng/mL and/or β‐HCG
5000‐50 000 mIU/mL and/or LDH 1.5‐10 U/L upper normal limit; S3, AFP > 10 000 ng/mL and/or β‐HCG > 50 000 mIU/mL and/or LDH > 10 U/L upper
normal limit; SEM, standard error of the mean.
*Cut‐off for miR‐371a‐3p = 6.89, based on optimal separation of healthy donors and primary (T)GCT patients.
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The associations between the histological subtypes of the pri-
mary (T)GCT and the plasma miR‐371a‐3p levels are summarized in
Table S4. Within the whole group, there was no association between
histology of primary tumour and plasma miR‐371a‐3p levels. In stage
I disease, there were no differences in plasma miR‐371a‐3p levels
based on histology of primary tumour.
Analysis of 101 paired samples (corresponding samples before
starting of first cycle and second cycle of chemotherapy) showed
that mean plasma level of miR‐371a‐3p was significantly higher
before the first cycle compared to the second cycle of chemotherapy
(mean ± SEM = 33.6 ± 8.1 vs. 0.2 ± 0.1, P < 0.00001) (Figure 1). Of
53 patients (52.5%) that were positive for pretreatment miR‐371a‐
3p, only two patients (3.8%), remained positive, one with significant
(from 99.9 to 1.5) and second with minor decrease (from 3.3 to 2.2)
of plasma miR‐371a‐3p, while two patients (2.0%), initially miR‐371a‐
3p negative, became positive before the second cycle of chemother-
apy (Figure S2A,B).
3.3 | Association between serum tumour markers
and plasma miR‐371a‐3p levels
There was correlation between miR‐371a‐3p continuous levels and
serum AFP and LDH, and between miR‐371a‐3p dichotomized and
LDH (Table 3, Figure S3A). There was a moderate correlation between
serum tumour markers defined as S‐stage and plasma miR‐371a‐3p
(Table 3, Figure S3B) This was consistent both for seminoma patients
(correlation coefficient = 0.32, P = 0.02 as continuous variable and
0.46, P = 0.0006 for dichotomized variable) as well as for non‐semi-
noma patients (correlation coefficient = 0.42, P < 0.00001 as continu-
ous variable and 0.48, P < 0.00001 for dichotomized miR‐371a‐3p).
In the 101 patients with paired samples, plasma miR‐371a‐3p
positivity before the treatment was in 53 (52.5%) of patients, while
positivity of serum tumour markers (stage S1‐3) was present in 59
(58.4% of patients). After the first cycle of chemotherapy, only four
(4.0%) patients were miR‐371a‐3p positive while in 27 (26.7%)
patients, serum tumour markers remained elevated (P = 0.00005).
3.4 | Prognostic value of plasma miR‐371a‐3p
In the median follow‐up time of 20.9 months (range 0.1‐65.1 months),
15 patients (8.3%) experienced disease progression and 12 patients
(6.7%) died. Estimated 2‐year PFS and OS were 89.3%, 95% CI (84.3-
94.3%) and 92.2%, 95% CI (87.5-97.0%), respectively.
In patients with negative pretreatment plasma miR‐371a‐3p
levels, the biomarker was associated with significantly better PFS
and OS compared to patients miR‐371a‐3p positive (hazard ratio
[HR] = 0.26, 95% CI 0.09-0.71, P = 0.02 for PFS and HR = 0.21,
95% CI 0.07-0.67, P = 0.03 for OS, respectively) (Table 4, Fig-
ure S2A,B). Only three (3.5%) of the patients with negative pretreat-
ment levels of miR‐371a‐3p experienced disease progression and
two (2.3%) of the patients died during follow up (median survival
20.9 months). While in seminoma patients the pretreatment plasma
levels of miR‐371a‐3p were not prognostic (HR = 1.19, 95% CI 0.19-
7.39, P = 0.85 for PFS and HR = 1.04, 95% CI 0.09-11.65, P = 0.98
for OS, respectively) (Figure S4A,B), in non‐seminoma pretreatment
plasma levels of miR‐371a‐3p were significantly associated with
patients outcome (HR = 0.10, 95% CI 0.03-0.33, P = 0.006 for PFS
and HR = 0.11, 95% CI 0.03-0.41, P = 0.01 for OS, respectively)
(Figure 2C,D). In subgroups of patients with negative serum tumour
markers (S0‐stage) plasma miR‐371a‐3p before the first or the sec-
ond cycle of chemotherapy was not associated with patients’ out-
come, however, only three disease progressions and one death were
observed in this subgroup of patients. No progression and/or death
was observed in patients with clinical stage IA/B disease. In meta-
static tumours (stage IS‐IIIC), negative pretreatment plasma miR‐
371a‐3p levels, the biomarker was associated with better PFS and
OS compared to patients miR‐371a‐3p positive (HR = 0.39, 95% CI
0.14-1.09, P = 0.13 for PFS and HR = 0.34, 95% CI 0.10-1.09,
P = 0.14 for OS, respectively).
In multivariate analysis, pretreatment plasma levels of miR‐371a‐
3p was not independently associated with IGCCCG risk group for
PFS (P = 0.20) or OS (P = 0.33) in the whole population (Table 4)
nor in the non‐seminoma subgroup (not shown), while IGCCCG risk
group category was associated with patients’ outcome irrespective
of plasma miR‐371a‐3p levels.
Plasma miR‐371a‐3p level before the second cycle of
chemotherapy (N = 101) was not prognostic for PFS or OS (HR =
F IGURE 1 Relative miR‐371a‐3p plasma level before the first and
second cycle of chemotherapy (hazard ratio [HR] = 0.26, 95%
confidence interval [CI] 0.09‐0.71, P = 0.02 for PFS and HR = 0.21,
95% CI 0.07‐0.67, P = 0.03 for OS, respectively) (Table 4, Figure 2A,B)
TABLE 3 Correlation between pretreatment plasma miR‐371a‐3p
and serum tumour markers
Variable
miR‐371a‐3p continuous miR‐371a‐3p dichotomized
Pearson
correlation P‐value
Pearson
correlation P‐value
AFP 0.26 0.0025 0.13 0.14
HCG −0.02 0.78 0.15 0.08
LDH 0.61 <0.00001 0.33 0.0001
S‐stage 0.41 <0.00001 0.42 <0.00001
Statistically significant indicated bold.
HCG, human chorionic gonadotropin; AFP, alpha‐fetoprotein; LDH, lac-
tate dehydrogenase.
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0.38, 95% CI 0.02-8.74, P = 0.35 for PFS and HR = 0.30, 95% CI
0.01-9.99, P = 0.22 for OS, respectively) in the whole population
nor in the seminoma or non‐seminoma subgroup (data not
shown).
In the subgroup of 101 patients with samples available before
the first and the second cycle of chemotherapy, patients with a
negative miR‐371a‐3p measurement in both samples had a signifi-
cantly superior PFS (HR = 0.10, 95% CI 0.01-21.49, P = 0.02) and
OS (HR = 0.08, 95% CI 0.01-27.81, P = 0.008) compared to patients
with miR‐371a‐3p positive in both samples. Patients with at least
one positive miR‐371a‐3p sample (baseline, before the second cycle
or both) had non‐significantly inferior outcome compared to patients
TABLE 4 Prognostic value of plasma miR‐371a‐3p before the first cycle of chemotherapy
Variable
HR (95% CI), P‐value
Progression‐free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Plasma miR‐371a‐3p
Negative vs. positive 0.26 (0.09‐0.71), 0.02 0.40 (0.11‐1.47), 0.20 0.21 (0.07‐0.67), 0.03 0.42 (0.09‐1.98), 0.33
IGCCCG risk group
Good risk vs. intermediate/poor risk 0.15 (0.05‐0.51), 0.0001 0.19 (0.06‐0.58), 0.003 0.07 (0.02‐0.25), <0.00001 0.08 (0.020.39), 0.002
Statistically significant indicated bold.
F IGURE 2 Kaplan‐Meier estimates of probabilities of: (A) progression‐free survival according to relative pretreatment miR‐371a‐3p plasma
level in (testicular) germ cell tumour patients (n = 180) (hazard ratio [HR] = 0.26, 95% confidence interval [CI] 0.09‐0.71, P = 0.02). Cut‐off for
miR‐371a‐3p = 1, based on optimal separation of healthy donors and primary (T)GCT patients was used to dichotomize the miRNA test
ampTSmiR; (B) overall survival according to relative pretreatment miR‐371a‐3p plasma level in (testicular) germ cell tumour patients (n = 180)
(HR = 0.21, 95% CI 0.07‐0.67, P = 0.03); (C) progression‐free survival according to relative pretreatment miR‐371a‐3p plasma level in non‐
seminoma patients (n = 129) (HR = 0.10, 95% CI 0.03‐0.33, P = 0.006). Cut‐off for miR‐371a‐3p = 1, based on optimal separation of healthy
donors and primary (T)GCT patients was used to dichotomize the microRNA‐371a‐3p ampTSmiR test; and (D) overall survival according to
relative pretreatment miR‐371a‐3p plasma level in non‐seminoma patients (n = 129) (HR = 0.11, 95% CI 0.03‐0.41, P = 0.01)
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with negative miR‐371a‐3p in both samples (HR = 0.18, 95% CI
0.10-1.34, P = 0.18 for PFS and HR = 0.19, 95% CI 0.10-1.35,
P = 0.19 for OS).
4 | DISCUSSION
In this translational study, we observed a number of associations
between several disease characteristics and pretreatment plasma
miR‐371a‐3p, including IGCCCG risk group, number of metastatic
sites, presence of lung, retroperitoneal and mediastinal lymph node
metastases, S – stage, and favourable response to therapy. More-
over, these associations were consistent for plasma levels of miR‐
371a‐3p analysed as continuous or dichotomized variable (except for
response to therapy).
Plasma miR‐371a‐3p levels were not clearly associated with any
histological subtype within the group cohort. This could be due to
the low number of more differentiated subtypes like teratoma and
or choriocarcinoma and yolk sac tumours. In another study, dysger-
minomas possess higher tumour expression of miR‐371a‐3p com-
pared to mixed GCT germ cell tumours that is consistent with our
data.20 When we analysed stage I patients separately, there were no
differences in plasma miR‐371a‐3p levels based on histology of pri-
mary tumour. At the time of analysis all but two patients had a per-
sisting primary (T)GCT, 75% of them had metastases while 25% had
no remaining tumour. Metastases and primary tumours may have
different histologies particularly in those with mixed GCT (the largest
group in this cohort). Therefore, the list of histologies is not neces-
sarily identical with the spectrum of histologies actually present at
the time of analysis. Therefore, much of the inconsistencies with
previous work10,14 may come from uncertain histologies. For exam-
ple, all teratoma patients had elevated serum tumour markers (four
patients were S1, one patient S2, and one patient S3) including ele-
vated β‐HCG in three of them suggesting other histologic compo-
nent in addition to teratoma was present in metastatic sites.
In our study, only 51.7% of the present patients with (T)GCT had
elevated levels of miRNA before chemotherapy as opposed to rates
around 90% reported in previous studies.10,14 This is most likely
explained by the fact that in this study the measurements were per-
formed just prior to the start of chemotherapy and not at the
moment of orchiectomy. The aim of the study was to show the
prognostic value of miR‐371a‐3p in (T)GCTs and not to compare the
survival of miR‐371a‐3p positive (T)GCT patients to a healthy popu-
lation.
Plasma miR‐371a‐3p positivity was found in 13.3% of patients
with clinical stage I disease after orchiectomy only. Surprisingly,
there was no association between plasma miR‐371a‐3p levels and
some prognostic factors associated with poor outcome, like non‐pul-
monary visceral metastases or extragonadal GCTs suggesting that
miR‐371a‐3p is indeed a marker associated with tumour burden as
suggested before,10 also in line with the finding that this miR is
expressed in all histological elements except teratoma, rather than
with treatment resistance. Subgroup analysis revealed that this
association is mainly triggered by non‐seminomatous histology. How-
ever numerically, in seminoma similar trends were observed as in
non‐seminoma.
In our study we observed for the first‐time prognostic value of
pretreatment plasma levels of miR‐371a‐3p for PFS and OS in (T)
GCTs. Subgroup analysis suggested limited prognostic value in semi-
noma patients and patients with negative serum tumour markers,
e.g. subgroups for whom, the disease response could be evaluated
only with imaging studies. However, extremely good prognosis of
these subgroups and low number of events preclude to draw any
definitive conclusion about the prognostic value of plasma miR‐
371a‐3p in these subgroups. Multivariate analysis did not show
prognostic value of plasma miR‐371a‐3p levels independently of
IGCCCG risk category, an observation that is consistent with strong
correlation between several IGCCCG risk factors and plasma miR‐
371a‐3p level. Sharp decline in positivity of plasma miR‐371a‐3p
after one cycle of cisplatin‐based chemotherapy compared to serum
tumour markers suggest rapid clearance of miR‐371a‐3p, in agree-
ment with a recent study10 and implies that plasma miR‐371a‐3p
changes could be early, very sensitive predictor of treatment effect
in TGCTs.14,21
Plasma miR‐371a‐3p before the second cycle of chemotherapy
showed no prognostic value in the whole patient population, proba-
bly due to rapid normalization of plasma miR‐371a‐3p after even
one cycle of chemotherapy, an observation consistent with a previ-
ous study.10 On the other hand, patients with positive miR‐371a‐3p
in both samples had inferior outcome compared to continuously neg-
ative patients, suggesting that persistence of plasma miR‐371a‐3p
positivity could be an early marker of treatment failure in TGCTs.
However, due to the low number of patients in subgroups, these
results should be confirmed in future studies.
Despite several strengths, this study has some limitations as well,
including the retrospective nature of the analysis. Even though this is
currently the largest study evaluating plasma miR‐371a‐3p clinical
utility in this patient population, low number of events due to very
good prognosis of TGCTs preclude from drawing definitive conclu-
sions in some subpopulation of patients. Moreover, due to the low
number of events in subgroups for whom the clinical utility of plasma
miR‐371a‐3p could be largest due to negativity of serum tumour
markers (S0‐stage disease and/or seminoma), we cannot assess the
real clinical utility of plasma miR‐371a‐3p in these subgroups. In the
study presented here the levels of miR‐371a‐3p have been investi-
gated. We reported an AUC of 0.951, with an 89% specificity and
90% sensitivity for miR‐371a‐3p and an AUC of 0.962 for the combi-
nation of the miRs with specificity of 92% and sensitivity of 91%.14
However, in our most recent studies addition of the extra miRs com-
pared to miR‐371a‐3p did not improve the outcome.13,18 In addition,
other studies are based on only using miR‐371.10,16,21
In this large translational study we showed for the first time an
association between plasma miR‐371a‐3p level and several disease
characteristics including sites of metastases, serum tumour markers,
IGCCCG prognostic group or favourable response to chemotherapy
measured at the time just prior to the start of chemotherapy.
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Moreover, we observed prognostic value of plasma miR‐371a‐3p in
chemotherapy‐naïve GCT patients starting first line of chemotherapy
as well as prognostic value of plasma miR‐371a‐3p changes during
the treatment suggesting clinical utility of plasma miR‐371a‐3p in
TGCTs.
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